Valproate induces epigenetic modifications in lymphomonocytes from epileptic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 47-51

  Tremolizzo, Lucio ^a,b   DiFrancesco, Jacopo C ^a,b   Rodriguez Menendez, Virginia ^b   Riva, Chiara ^b   Conti, Elisa ^b   Galimberti, Gloria ^b   Ruffmann, Claudio ^a,b   Ferrarese, Carlo ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

DNA methylation; Epimutations; Histone acetylation; Valproate

Indexed keywords

HISTONE H3; PHENOBARBITAL; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA MODIFICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; EPIGENETICS; EPILEPSY; FEMALE; GENETIC MARKER; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MENTAL DISEASE; MONOTHERAPY; NORMAL HUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION;

ACETYLATION; ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; EPIGENOMICS; EPILEPSY; FEMALE; HISTONES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHENOBARBITAL; VALPROIC ACID;

EID: 84864506892     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.016     Document Type: Article

References (36)

1. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991, 20:114-122.
2. Beutler A.S., Li S., Nicol R., Walsh M.J. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 2005, 76:3107-3115.
3. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005, 25:383-397.
4. Cervera E., Candelaria M., López-Navarro O., Labardini J., Gonzalez-Fierro A., Taja-Chayeb L., et al. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2012, 12:207-212.
5. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010. pii, 479364.
6. Chávez-Blanco A., De la Cruz-Hernández E., Domínguez G.I., Rodríguez-Cortez O., Alatorre B., Pérez-Cárdenas E., et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 2011, 39:1491-1499.
7. Detich N., Bovenzi V., Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003, 278:27586-27592.
8. Dong E., Chen Y., Gavin D.P., Grayson D.R., Guidotti A. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 2010, 5:730-735.
9. Eikel D., Hoffmann K., Zoll K., Lampen A., Nau H. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug Metab Dispos 2006, 34:612-620.
10. Eyal S., Yagen B., Sobol E., Altschuler Y., Shmuel M., Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004, 45:737-744.
11. Frikeche J., Simon T., Brissot E., Grégoire M., Gaugler B., Mohty M. Impact of valproic acid on dendritic cells function. Immunobiology 2012, 217:704-710.
12. Gottlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
13. Guidotti A., Auta J., Chen Y., Davis J.M., Dong E., Gavin D.P., et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011, 60:1007-1016.
14. Hrebackova J., Hrabeta J., Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 2010, 11:361-379.
15. Huang Y., Doherty J.J., Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J Neurosci 2002, 22:8422-8428.
16. Hoffmann K., Czapp M., Loscher W. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?. Epilepsy Res 2008, 81:107-113.
17. Karapidaki I., Ekonomopoulou M.T., Akritopoulou K., Anestakis D., Iakovidou-Kritsi Z. Cytogenetic effects of valproic acid and ziprasidone in human lymphocyte cultures. Neuropsychobiology 2011, 64:219-223.
18. Kobow K., Blümcke I. The methylation hypothesis: do epigenetic chromatin modifications play a role in epileptogenesis?. Epilepsia 2011, 52(Suppl. 4):15-19.
19. Löscher W. Basic pharmacology of valproate: a review after 35years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
20. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009, 2:95-109.
21. Nalivaeva N.N., Belyaev N.D., Turner A.J. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 2009, 30:509-514.
22. Perisic T., Zimmermann N., Kirmeier T., Asmus M., Tuorto F., Uhr M., et al. Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 2010, 35:792-805.
23. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35years of clinical experience. CNS Drugs 2002, 16:695-714.
24. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
25. Pogribny I., Yi P., James S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun 1999, 262:624-628.
26. Radatz M., Ehlers K., Yagen B., Bialer M., Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998, 30:41-48.
27. Sharma R.P., Rosen C., Kartan S., Guidotti A., Costa E., Grayson D.R., et al. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr Res 2006, 88:227-231.
28. Singh G., Driever P.H., Sander J.W. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005, 128:7-17.
29. Stapleton S.L., Thompson P.A., Ou C.N., Berg S.L., McGuffey L., Gibson B., et al. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol 2008, 61:647-652.
30. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 2002, 99:17095-17100.
31. Tremolizzo L., Doueiri M.S., Dong E., Grayson D.R., Davis J., Pinna G., et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005, 57:500-509.
32. Tsai L.K., Tsai M.S., Ting C.H., Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 2008, 86:1243-1254.
33. Tsai H.C., Wei K.C., Tsai C.N., Huang Y.C., Chen P.Y., Chen S.M., et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg. 2012, 26:347-354.
34. Tung E.W., Winn L.M. Epigenetic modifications in valproic acid-induced teratogenesis. Toxicol Appl Pharmacol 2010, 248:201-209.
35. Weller M., Gorlia T., Cairncross J.G., van den Bent M.J., Mason W., Belanger K., et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164.
36. Zadori D., Geisz A., Vamos E., Vecsei L., Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 2009, 94:148-153.